NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the Committee, and, if so, how?

Consultees at the workshop were asked to consider the availability of the technology to all socioeconomic groups, given that the incidence of bladder cancer is higher in lower socioeconomic groups.

Consultees agreed that this was not classed an equalities issue as it was a matter of ensuring equity of access rather than treatment. The scope did not define the population by any of the protected characteristics outlined in the equalities legislation, therefore no changes to the draft scope were necessary.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the Committee addressed these?

No equality issues were raised in the submissions, statements or academic report.

3. Have any other potential equality issues been identified by the Committee, and, if so, how has the Committee addressed these?

Technology appraisals: Guidance development
Equality impact assessment for the single technology appraisal of vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract
Issue date: December 2012
1 of 3
4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

No.

5. Are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to access identified in question 4, or otherwise fulfil NICE’s obligations to promote equality?

N/A

6. Have the Committee’s considerations of equality issues been described in the appraisal consultation document, and, if so, where?

No equality issues were identified in this appraisal.

Approved by Associate Director (name): Helen Chung

Date: 18/11/2010

Final appraisal determination (pre-appeal FAD issued March 2011 and post-appeal FAD)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed these?

The manufacturer raised the issue of relative access to vinflunine that NHS Patients have compared to elsewhere in Europe. Provision of healthcare and therefore decisions on access to treatments in England and Wales are based...
on national criteria. This is not an equalities issue under the relevant equality legislation.

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2.</td>
<td>If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?</td>
</tr>
<tr>
<td></td>
<td>Not applicable</td>
</tr>
<tr>
<td>3.</td>
<td>If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?</td>
</tr>
<tr>
<td></td>
<td>Not applicable</td>
</tr>
<tr>
<td>4.</td>
<td>If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?</td>
</tr>
<tr>
<td></td>
<td>Not applicable</td>
</tr>
<tr>
<td>5.</td>
<td>Have the Committee’s considerations of equality issues been described in the final appraisal determination, and, if so, where?</td>
</tr>
<tr>
<td></td>
<td>The Committee’s considerations are described in the summary table of the Committee’s key conclusions.</td>
</tr>
</tbody>
</table>

**Approved by Centre or Programme Director (name):** Meindert Boysen

**Date:** 06/11/2012

Technology appraisals: Guidance development
Equality impact assessment for the single technology appraisal of vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract

**Issue date:** December 2012